Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín
Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.
Novel therapy for the treatment of optic neuropathies by inhibition of semaphorin3A
Resumen
Tipo:
Oferta Tecnológica
Referencia:
TOES20200513005
Publicado:
03/06/2020
Caducidad:
04/06/2021
Resumen:
A Spanish research centre, has jointly developed with a Israeli university, a family of compounds able to inhibit Semaphorin3A fostering nerve regeneration after injury. These compounds can be useful for treatment of ischemic events such as stroke, glaucoma and other optical nerve and retina insults. Biotech or pharmaceutical companies are sought for license agreement and/or research collaboration to perform preclinical assays.
Details
Tittle:
Novel therapy for the treatment of optic neuropathies by inhibition of semaphorin3A
Summary:
A Spanish research centre, has jointly developed with a Israeli university, a family of compounds able to inhibit Semaphorin3A fostering nerve regeneration after injury. These compounds can be useful for treatment of ischemic events such as stroke, glaucoma and other optical nerve and retina insults. Biotech or pharmaceutical companies are sought for license agreement and/or research collaboration to perform preclinical assays.
Description:
After a neuronal damage is produced, Semaphorin3A (Sema3A) protein is highly expressed as a response in adult mammalian central nervous system (CNS), preventing axon regeneration and promoting progressive neuronal apoptosis, even once the ischemic event is restored, leading to permanent damage.
Compounds presented are able to modulate neurodegeneration by inhibiting Sema3A pathway, thus stimulating injured axons regeneration and brain repair.
Their therapeutic potential has been proved in pre-clinical (in vitro and in vivo) assays involving injure of the optic nerve. The Sema3A inhibitors were able to prevent loss of retinal ganglion cells (RGC) in a range of harsh optic degenerative insults using in vivo models, such as optical nerve transection in adult rats. Results showed between 30-40% of RGC survival after treatment with the compounds.
The research centres, with broad experience in medicinal chemistry and in ophtalmic research, are searching for a biotech or pharmaceutical company interested in the preclinical and clinical development of a treatment for optic neuropathies, under a license agreement. The centres could collaborate with the company in that project through a research collaboration.
Compounds presented are able to modulate neurodegeneration by inhibiting Sema3A pathway, thus stimulating injured axons regeneration and brain repair.
Their therapeutic potential has been proved in pre-clinical (in vitro and in vivo) assays involving injure of the optic nerve. The Sema3A inhibitors were able to prevent loss of retinal ganglion cells (RGC) in a range of harsh optic degenerative insults using in vivo models, such as optical nerve transection in adult rats. Results showed between 30-40% of RGC survival after treatment with the compounds.
The research centres, with broad experience in medicinal chemistry and in ophtalmic research, are searching for a biotech or pharmaceutical company interested in the preclinical and clinical development of a treatment for optic neuropathies, under a license agreement. The centres could collaborate with the company in that project through a research collaboration.
Advantages and Innovations:
· The small molecules developed act as prolonged inhibitors of Sema3A apoptotic pathway.
· Application for treatment in the prevention of RGC loss associated to different optic neuropathies, currently ineffective, is envisioned thus promoting nerve regeneration.
· Potential application to other neurodegenerative processes associated to CNS disorders.
· Application for treatment in the prevention of RGC loss associated to different optic neuropathies, currently ineffective, is envisioned thus promoting nerve regeneration.
· Potential application to other neurodegenerative processes associated to CNS disorders.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
European patent application filed
Partner sought
Type and Role of Partner Sought:
Biotech or pharmaceutical companies interesed in the development of treatments for optic neuropathies.
-Licensing agreement: the partner would license the technology to perform clinical assays, obtain all regulatory
certifications and commercialize the drug.
-Research cooperation agreement: the partner and the institution could undertake a joint effort to perform preclinical
assays.
-Licensing agreement: the partner would license the technology to perform clinical assays, obtain all regulatory
certifications and commercialize the drug.
-Research cooperation agreement: the partner and the institution could undertake a joint effort to perform preclinical
assays.
Client
Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish
Spanish
Keywords
Technology Keywords:
06001002 Investigaciones clínicas, ensayos
06001014 Neurología, investigación cerebral
06001015 Productos farmacéuticos / medicamentos
06001014 Neurología, investigación cerebral
06001015 Productos farmacéuticos / medicamentos
een_ader
